We noted that dynamic changes in PP2A activity were contrary to ERK activity in response to different concentrations of EF-24 treatment in HL-60 and MV4-11 AML cells (Figure 3B, Figure 5B, and Figure S5). The gene discussed is PTPA; the disease is acute myeloid leukemia.